EDITAS MEDICINE, INC. Increase (Decrease) in Other Noncurrent Liabilities
EDITAS MEDICINE, INC. (EDIT) reported Increase (Decrease) in Other Noncurrent Liabilities of -$402.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-05
- EDITAS MEDICINE, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was -$454.00K.
- EDITAS MEDICINE, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was $52.00K, a 98.39% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$1.81M.
- EDITAS MEDICINE, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was $95.00K.
- EDITAS MEDICINE, INC. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $192.00K, a 84.89% decline from fiscal 2024.
- EDITAS MEDICINE, INC. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $1.27M.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$402.00K 10-Q · filed 2026-08-05 | -$2.22M derived: sum of 3 quarters · filed 2026-08-05 | -$2.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $52.00K 10-Q · filed 2026-05-05 | -$1.76M derived: sum of 2 quarters · filed 2026-05-05 | -$1.67M derived: sum of 3 quarters · filed 2026-05-05 | -$2.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.72M derived: sum of 2 quarters · filed 2026-03-09 | -$3.03M derived: sum of 3 quarters · filed 2026-08-05 | $192.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.22M derived: sum of 2 quarters · filed 2026-08-05 | $2.01M 10-Q · filed 2025-11-10 | $1.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.91M 10-Q · filed 2026-08-05 | $1.70M derived: sum of 3 quarters · filed 2026-08-05 | $1.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.22M 10-Q · filed 2026-05-05 | $3.01M derived: sum of 2 quarters · filed 2026-05-05 | $2.52M derived: sum of 3 quarters · filed 2026-05-05 | $2.82M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$698.00K derived: sum of 2 quarters · filed 2026-03-09 | -$402.00K derived: sum of 3 quarters · filed 2026-03-09 | $1.27M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$488.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$192.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.48M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.97M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $1.67M 10-Q · filed 2025-05-12 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |